Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 24;9:9195. doi: 10.1038/s41598-019-45477-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

PAX1 promoter methylation status in cervical cancer, and association with decreased progression-free (PFS) and overall (OS) survival. (A) Methylation status of PAX1 in cervical cancer. Displayed are the methylation levels of three patients, who donated both tumor and non-tumor specimens. T, tumor tissue; N, normal tissue. The analyzed probes were located in the CpG island (chr20:21686200-21687689) of PAX1 promoter. (B) Kaplan–Meier plots of the probability of PFS and OS, stratified according to the methylation status of PAX1, in patients with cervical cancer. (C) Proposed model of PAX1-induced phosphatase expression, and disruption of EGF signaling.